{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:34:43Z","timestamp":1792812883191,"version":"4.5.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Alexion Pharma GK, AstraZeneca Rare Disease"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s40120-025-00850-7","type":"journal-article","created":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T02:33:30Z","timestamp":1762914810000},"page":"127-141","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Clinical Impact of High-Dose Corticosteroids on Healthcare Resource Utilization and Steroid-Related Complications in Patients with Myasthenia Gravis in Japan"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-9873-721X","authenticated-orcid":false,"given":"Naoki","family":"Numajiri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takanori","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4648-7454","authenticated-orcid":false,"given":"Miina","family":"Waratani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5513-5012","authenticated-orcid":false,"given":"Masanori P.","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,12]]},"reference":[{"issue":"11","key":"850_CR1","doi-asserted-by":"publisher","first-page":"2843","DOI":"10.1172\/JCI29894","volume":"116","author":"BM Conti-Fine","year":"2006","unstructured":"Conti-Fine BM, Milani M, Kaminski HJ. Myasthenia gravis: past, present, and future. J Clin Invest. 2006;116(11):2843\u201354.","journal-title":"J Clin Invest"},{"issue":"2","key":"850_CR2","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.ncl.2018.01.002","volume":"36","author":"MK Hehir","year":"2018","unstructured":"Hehir MK, Silvestri NJ. Generalized myasthenia gravis: classification, clinical presentation, natural history, and epidemiology. Neurol Clin. 2018;36(2):253\u201360.","journal-title":"Neurol Clin"},{"issue":"1","key":"850_CR3","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1186\/s12967-021-03185-7","volume":"19","author":"N Salari","year":"2021","unstructured":"Salari N, Fatahi B, Bartina Y, et al. Global prevalence of myasthenia gravis and the effectiveness of common drugs in its treatment: a systematic review and meta-analysis. J Transl Med. 2021;19(1):516.","journal-title":"J Transl Med"},{"issue":"9","key":"850_CR4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0274161","volume":"17","author":"H Yoshikawa","year":"2022","unstructured":"Yoshikawa H, Adachi Y, Nakamura Y, et al. Two-step nationwide epidemiological survey of myasthenia gravis in Japan 2018. PLoS ONE. 2022;17(9):e0274161.","journal-title":"PLoS ONE"},{"key":"850_CR5","volume":"2012","author":"A Jayam Trouth","year":"2012","unstructured":"Jayam Trouth A, Dabi A, Solieman N, et al. Myasthenia gravis: a review. Autoimmune Dis. 2012;2012:874680.","journal-title":"Autoimmune Dis"},{"key":"850_CR6","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s12955-015-0298-1","volume":"13","author":"MI Boldingh","year":"2015","unstructured":"Boldingh MI, Dekker L, Maniaol AH, et al. An up-date on health-related quality of life in myasthenia gravis -results from population based cohorts. Health Qual Life Outcomes. 2015;13:115.","journal-title":"Health Qual Life Outcomes"},{"issue":"5","key":"850_CR7","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-068104","volume":"13","author":"S Berrih-Aknin","year":"2023","unstructured":"Berrih-Aknin S, Palace J, Meisel A, et al. Patient-reported impact of myasthenia gravis in the real world: findings from a digital observational survey-based study (MyRealWorld MG). BMJ Open. 2023;13(5):e068104.","journal-title":"BMJ Open"},{"issue":"4","key":"850_CR8","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1007\/s40120-024-00617-6","volume":"13","author":"N Kawaguchi","year":"2024","unstructured":"Kawaguchi N, Tsuda K, Tanaka N, et al. Myasthenia gravis disease burden and its impact on satisfaction with life: a qualitative survey of patients\u2019 perspectives in Japan. Neurol Ther. 2024;13(4):1099\u2013113.","journal-title":"Neurol Ther"},{"issue":"1","key":"850_CR9","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s12325-023-02704-w","volume":"41","author":"S Dewilde","year":"2024","unstructured":"Dewilde S, Phillips G, Paci S, et al. The burden patients with myasthenia gravis experience in terms of breathing, fatigue, sleep, mental health, discomfort and usual activities in comparison to the general population. Adv Ther. 2024;41(1):271\u201391.","journal-title":"Adv Ther"},{"issue":"1","key":"850_CR10","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s13023-023-02727-0","volume":"18","author":"M Mahic","year":"2023","unstructured":"Mahic M, Bozorg A, DeCourcy J, et al. Physician- and patient-reported perspectives on myasthenia gravis in Europe: a real-world survey. Orphanet J Rare Dis. 2023;18(1):169.","journal-title":"Orphanet J Rare Dis"},{"issue":"6","key":"850_CR11","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16180","volume":"31","author":"F Sacc\u00e0","year":"2024","unstructured":"Sacc\u00e0 F, Salort-Campana E, Jacob S, et al. Refocusing generalized myasthenia gravis: patient burden, disease profiles, and the role of evolving therapy. Eur J Neurol. 2024;31(6):e16180.","journal-title":"Eur J Neurol"},{"key":"850_CR12","doi-asserted-by":"publisher","DOI":"10.1177\/17562864221150327","volume":"16","author":"M Mahic","year":"2023","unstructured":"Mahic M, Bozorg A, Rudnik J, et al. Healthcare resource use in myasthenia gravis: a US health claims analysis. Ther Adv Neurol Disord. 2023;16:17562864221150327.","journal-title":"Ther Adv Neurol Disord"},{"issue":"1","key":"850_CR13","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/cen3.12739","volume":"14","author":"H Murai","year":"2023","unstructured":"Murai H, Utsugisawa K, Motomura M, et al. The Japanese clinical guidelines 2022 for myasthenia gravis and Lambert-Eaton myasthenic syndrome. Clin Exp Neuroimmunol. 2023;14(1):19\u201327.","journal-title":"Clin Exp Neuroimmunol"},{"issue":"3","key":"850_CR14","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","volume":"96","author":"P Narayanaswami","year":"2021","unstructured":"Narayanaswami P, Sanders DB, Wolfe G, et al. International consensus guidance for management of myasthenia gravis: 2020 update. Neurology. 2021;96(3):114\u201322.","journal-title":"Neurology"},{"issue":"4","key":"850_CR15","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1517\/14740338.2016.1140743","volume":"15","author":"M Oray","year":"2016","unstructured":"Oray M, Abu Samra K, Ebrahimiadib N, et al. Long-term side effects of glucocorticoids. Expert Opin Drug Saf. 2016;15(4):457\u201365.","journal-title":"Expert Opin Drug Saf"},{"issue":"1","key":"850_CR16","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1159\/000322497","volume":"65","author":"Y Nagane","year":"2011","unstructured":"Nagane Y, Suzuki S, Suzuki N, et al. Early aggressive treatment strategy against myasthenia gravis. Eur Neurol. 2011;65(1):16\u201322.","journal-title":"Eur Neurol"},{"issue":"1","key":"850_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/bmjmed-2022-000241","volume":"2","author":"M DeHart-McCoyle","year":"2023","unstructured":"DeHart-McCoyle M, Patel S, Du X. New and emerging treatments for myasthenia gravis. BMJ Med. 2023;2(1):e000241.","journal-title":"BMJ Med"},{"issue":"4","key":"850_CR18","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s00774-014-0586-6","volume":"32","author":"Y Suzuki","year":"2014","unstructured":"Suzuki Y, Nawata H, Soen S, et al. Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research: 2014 update. J Bone Miner Metab. 2014;32(4):337\u201350.","journal-title":"J Bone Miner Metab"},{"issue":"2","key":"850_CR19","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s00774-024-01502-w","volume":"42","author":"Y Tanaka","year":"2024","unstructured":"Tanaka Y, Soen S, Hirata S, et al. The 2023 guidelines for the management and treatment of glucocorticoid-induced osteoporosis. J Bone Miner Metab. 2024;42(2):143\u201354.","journal-title":"J Bone Miner Metab"},{"issue":"5","key":"850_CR20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0126579","volume":"10","author":"S Konno","year":"2015","unstructured":"Konno S, Suzuki S, Masuda M, et al. Association between glucocorticoid-induced osteoporosis and myasthenia gravis: a cross-sectional study. PLoS ONE. 2015;10(5):e0126579.","journal-title":"PLoS ONE"},{"key":"850_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2024.123017","volume":"460","author":"S Konno","year":"2024","unstructured":"Konno S, Uchi T, Kihara H, et al. Ten-year fracture risk in Japanese patients with myasthenia gravis: a comprehensive assessment using the fracture risk assessment tool. J Neurol Sci. 2024;460:123017.","journal-title":"J Neurol Sci"},{"issue":"6","key":"850_CR22","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1093\/jbmr\/zjae043","volume":"39","author":"HS Park","year":"2024","unstructured":"Park HS, Kim K, Yu MH, et al. Risk of fracture in patients with myasthenia gravis: a nationwide cohort study in Korea. J Bone Miner Res. 2024;39(6):688\u201396.","journal-title":"J Bone Miner Res"},{"issue":"2","key":"850_CR23","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s00198-012-1970-5","volume":"24","author":"S Pouwels","year":"2013","unstructured":"Pouwels S, de Boer A, Javaid MK, et al. Fracture rate in patients with myasthenia gravis: the general practice research database. Osteoporos Int. 2013;24(2):467\u201376.","journal-title":"Osteoporos Int"},{"issue":"3","key":"850_CR24","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1007\/s00198-021-06101-3","volume":"33","author":"Z Safipour","year":"2022","unstructured":"Safipour Z, van der Zanden R, van den Bergh J, et al. The use of oral glucocorticoids and the risk of major osteoporotic fracture in patients with myasthenia gravis. Osteoporos Int. 2022;33(3):649\u201358.","journal-title":"Osteoporos Int"},{"issue":"12","key":"850_CR25","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1212\/WNL.0000000000000804","volume":"83","author":"JH Yeh","year":"2014","unstructured":"Yeh JH, Chen HJ, Chen YK, et al. Increased risk of osteoporosis in patients with myasthenia gravis: a population-based cohort study. Neurology. 2014;83(12):1075\u20139.","journal-title":"Neurology"},{"issue":"12","key":"850_CR26","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1093\/rheumatology\/39.12.1383","volume":"39","author":"TP van Staa","year":"2000","unstructured":"van Staa TP, Leufkens HG, Abenhaim L, et al. Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (Oxford). 2000;39(12):1383\u20139.","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"850_CR27","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1002\/art.21984","volume":"55","author":"JR Curtis","year":"2006","unstructured":"Curtis JR, Westfall AO, Allison J, et al. Population-based assessment of adverse events associated with long-term glucocorticoid use. Arthritis Rheum. 2006;55(3):420\u20136.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"850_CR28","doi-asserted-by":"publisher","first-page":"3462","DOI":"10.1007\/s00415-024-12293-5","volume":"271","author":"L Fuchs","year":"2024","unstructured":"Fuchs L, Shelly S, Vigiser I, et al. Real-world experience with efgartigimod in patients with myasthenia gravis. J Neurol. 2024;271(6):3462\u201370.","journal-title":"J Neurol"},{"issue":"8","key":"850_CR29","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1002\/acn3.52142","volume":"11","author":"S Luo","year":"2024","unstructured":"Luo S, Jiang Q, Zeng W, et al. Efgartigimod for generalized myasthenia gravis: a multicenter real-world cohort study in China. Ann Clin Transl Neurol. 2024;11(8):2212\u201321.","journal-title":"Ann Clin Transl Neurol"},{"issue":"9","key":"850_CR30","doi-asserted-by":"publisher","first-page":"6209","DOI":"10.1007\/s00415-024-12588-7","volume":"271","author":"C Pane","year":"2024","unstructured":"Pane C, Di Stefano V, Cuomo N, et al. A real-life experience with eculizumab and efgartigimod in generalized myasthenia gravis patients. J Neurol. 2024;271(9):6209\u201319.","journal-title":"J Neurol"},{"issue":"3","key":"850_CR31","doi-asserted-by":"publisher","DOI":"10.1212\/CPJ.0000000000200276","volume":"14","author":"S Suzuki","year":"2024","unstructured":"Suzuki S, Uzawa A, Nagane Y, et al. Therapeutic responses to egartigimod for generalized myasthenia gravis in Japan. Neurol Clin Pract. 2024;14(3):e200276.","journal-title":"Neurol Clin Pract"},{"issue":"4","key":"850_CR32","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1111\/cen3.12716","volume":"13","author":"H Murai","year":"2022","unstructured":"Murai H, Suzuki S, Fukamizu Y, et al. Safety and effectiveness of eculizumab in Japanese patients with generalized myasthenia gravis: analysis of 1-year postmarketing surveillance. Clin Exp Neuroimmunol. 2022;13(4):280\u20139.","journal-title":"Clin Exp Neuroimmunol"},{"issue":"7_Supplement_1","key":"850_CR33","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000208765","volume":"104","author":"C Scheiner","year":"2025","unstructured":"Scheiner C, Macwan S, Streicher N, et al. Outcomes for patients with generalized myasthenia gravis prescribed ravulizumab or efgartigimod treatment: a retrospective medical record analysis (P1\u201311.001). Neurology. 2025;104(7_Supplement_1):1820.","journal-title":"Neurology"},{"key":"850_CR34","doi-asserted-by":"publisher","first-page":"868","DOI":"10.3389\/fneur.2020.00868","volume":"11","author":"T Imai","year":"2020","unstructured":"Imai T, Suzuki S, Nagane Y, et al. Reappraisal of oral steroid therapy for myasthenia gravis. Front Neurol. 2020;11:868.","journal-title":"Front Neurol"},{"issue":"5","key":"850_CR35","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1002\/mus.24438","volume":"51","author":"T Imai","year":"2015","unstructured":"Imai T, Suzuki S, Tsuda E, et al. Oral corticosteroid therapy and present disease status in myasthenia gravis. Muscle Nerve. 2015;51(5):692\u20136.","journal-title":"Muscle Nerve"},{"issue":"5","key":"850_CR36","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1136\/jnnp-2017-316625","volume":"89","author":"T Imai","year":"2018","unstructured":"Imai T, Utsugisawa K, Murai H, et al. Oral corticosteroid dosing regimen and long-term prognosis in generalised myasthenia gravis: a multicentre cross-sectional study in Japan. J Neurol Neurosurg Psychiatry. 2018;89(5):513\u20137.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"850_CR37","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/cen3.12495","volume":"10","author":"H Murai","year":"2019","unstructured":"Murai H, Hasebe M, Murata T, et al. Clinical burden and healthcare resource utilization associated with myasthenia gravis: assessments from a Japanese claims database. Clin Exp Neuroimmunol. 2019;10(1):61\u20138.","journal-title":"Clin Exp Neuroimmunol"},{"key":"850_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.886625","volume":"13","author":"HJ Kaminski","year":"2022","unstructured":"Kaminski HJ, Denk J. Corticosteroid treatment-resistance in myasthenia gravis. Front Neurol. 2022;13:886625.","journal-title":"Front Neurol"},{"issue":"10","key":"850_CR39","doi-asserted-by":"publisher","first-page":"3781","DOI":"10.1007\/s00415-021-10520-x","volume":"268","author":"Y Ozawa","year":"2021","unstructured":"Ozawa Y, Uzawa A, Yasuda M, et al. Long-term outcomes and prognostic factors in generalized myasthenia gravis. J Neurol. 2021;268(10):3781\u20138.","journal-title":"J Neurol"},{"issue":"4","key":"850_CR40","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1097\/CND.0000000000000034","volume":"15","author":"NJ Silvestri","year":"2014","unstructured":"Silvestri NJ, Wolfe GI. Treatment-refractory myasthenia gravis. J Clin Neuromuscul Dis. 2014;15(4):167\u201378.","journal-title":"J Clin Neuromuscul Dis"},{"issue":"2","key":"850_CR41","first-page":"255","volume":"86","author":"J Suh","year":"2013","unstructured":"Suh J, Goldstein JM, Nowak RJ. Clinical characteristics of refractory myasthenia gravis patients. Yale J Biol Med. 2013;86(2):255\u201360.","journal-title":"Yale J Biol Med"},{"issue":"5","key":"850_CR42","volume":"11","author":"M Maeda","year":"2024","unstructured":"Maeda M, Shimomura H, Tokunaga S, et al. Clinical characteristics and treatment of juvenile myasthenia gravis-a single-center experience. Children (Basel). 2024;11(5):572.","journal-title":"Children (Basel)"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-025-00850-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-025-00850-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-025-00850-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T15:07:00Z","timestamp":1768403220000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-025-00850-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,12]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["850"],"URL":"https:\/\/doi.org\/10.1007\/s40120-025-00850-7","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,12]]},"assertion":[{"value":"23 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Naoki Numajiri is an employee of and holds stock or stock options in Alexion Pharma GK, AstraZeneca Rare Disease. Takanori Yamamoto is an employee of Alexion Pharma GK, AstraZeneca Rare Disease. Miina Waratani is a former employee of and holds stock or stock options in AstraZeneca. Masanori P. Takahashi reports unrestricted research grants from Astellas Pharma, Japan Blood Products Organization, and Mitsubishi Tanabe Pharma, outside of the submitted work, and honoraria from argenx, Alexion Pharmaceuticals, Immunovant, and UCB Pharma.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Participants and all applicable laws and regulations in Japan. The study protocol was approved by Alexion\u2019s Health Economics and Outcomes Research Review Committee. It was not necessary or practical to obtain informed consent for the use of secondary data in this study; however, all data in the JMDC was de-identified per the Act on the Protection of Personal Information, and no personal information could be restored in the database and no individual could be re-identified.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics\/Ethical Approval"}}]}}